CR20120303A - Tratamientos para trastornos gastrointestinales - Google Patents
Tratamientos para trastornos gastrointestinalesInfo
- Publication number
- CR20120303A CR20120303A CR20120303A CR20120303A CR20120303A CR 20120303 A CR20120303 A CR 20120303A CR 20120303 A CR20120303 A CR 20120303A CR 20120303 A CR20120303 A CR 20120303A CR 20120303 A CR20120303 A CR 20120303A
- Authority
- CR
- Costa Rica
- Prior art keywords
- treatments
- gastrointestinal disorders
- gastrointestinal
- useful
- treatment
- Prior art date
Links
- 208000018522 Gastrointestinal disease Diseases 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 208000010643 digestive system disease Diseases 0.000 abstract 1
- 208000018685 gastrointestinal system disease Diseases 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25926409P | 2009-11-09 | 2009-11-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20120303A true CR20120303A (es) | 2012-08-08 |
Family
ID=43503086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20120303A CR20120303A (es) | 2009-11-09 | 2012-06-06 | Tratamientos para trastornos gastrointestinales |
Country Status (26)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2559319T3 (es) | 2007-06-04 | 2016-02-11 | Synergy Pharmaceuticals Inc. | Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| US8034782B2 (en) | 2008-07-16 | 2011-10-11 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP2328910B1 (en) | 2008-06-04 | 2014-08-06 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| JP2012510518A (ja) * | 2008-12-02 | 2012-05-10 | アイロンウッド ファーマシューティカルズ，インコーポレーテッド | 体液貯留障害を処置するための方法および組成物 |
| GEP20166435B (en) * | 2009-11-09 | 2016-02-25 | Ironwood Pharmaceuticals Inc | Treatments for gastrointestinal disorders |
| CN102822194B (zh) * | 2009-12-07 | 2016-10-26 | 硬木药品公司 | 用于胃肠病症的治疗 |
| CA2835624A1 (en) * | 2011-05-11 | 2012-11-15 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| US9303066B2 (en) | 2011-05-11 | 2016-04-05 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| US20160213739A1 (en) * | 2011-05-11 | 2016-07-28 | Ironwood Pharmaceuticals, Inc | Treatments for disorders using guanylate cyclase c agonists |
| WO2012170804A1 (en) * | 2011-06-08 | 2012-12-13 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| WO2012170766A1 (en) * | 2011-06-08 | 2012-12-13 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| MX347354B (es) * | 2011-08-17 | 2017-04-24 | Ironwood Pharmaceuticals Inc | Tratamientos para trastornos gastrointestinales. |
| JP2016521249A (ja) * | 2012-07-12 | 2016-07-21 | フォレスト ラボラトリーズ ホールディングス リミテッド | リナクロチド組成物 |
| AU2014235215A1 (en) | 2013-03-15 | 2015-10-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| JP6694385B2 (ja) | 2013-08-09 | 2020-05-13 | アーデリクス，インコーポレーテッド | リン酸塩輸送阻害のための化合物及び方法 |
| US20160235807A1 (en) * | 2013-10-09 | 2016-08-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
| WO2016015055A1 (en) * | 2014-07-25 | 2016-01-28 | Ironwood Pharmaceuticals, Inc. | Colon cleansing compositions |
| EP3972599B1 (en) | 2019-05-21 | 2025-10-22 | Ardelyx, Inc. | Combination for lowering serum phosphate in a patient |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB290795A (en) | 1927-04-08 | 1928-05-24 | British Colour Printing Compan | Improvements in or relating to advertising or display devices |
| US5962220A (en) | 1993-10-26 | 1999-10-05 | Thomas Jefferson University | Compositions that specifically bind to colorectal cells and methods of using the same |
| US5601990A (en) | 1994-09-13 | 1997-02-11 | Thomas Jefferson University | Methods of diagnosing colorectal tumors and metastasis thereof |
| DE69433564T2 (de) | 1993-10-26 | 2004-12-23 | Thomas Jefferson University | Verbindungen, die kolorektale Krebszellen spezifisch binden, und Verfahren zu ihrer Verwendung |
| US5879656A (en) | 1993-10-26 | 1999-03-09 | Thomas Jefferson University | Methods of treating metastatic colorectal cancer with ST receptor binding compounds |
| US5518888A (en) | 1993-10-26 | 1996-05-21 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
| CH689139A5 (de) | 1995-04-03 | 1998-10-30 | Cerbios Pharma Sa | Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung. |
| US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| WO2001080871A2 (de) * | 2000-04-22 | 2001-11-01 | Ipf Pharmaceuticals Gmbh | Anwendung von guanylat-zyklase-c (gc-c) agonisten als insulinotrope faktoren zur behandlung von diabetes mellitus typ 2 |
| DK1594517T3 (da) | 2003-01-28 | 2007-10-29 | Microbia Inc | Sammensætninger til behandlingen af gastrointestinale lidelser |
| US7304036B2 (en) | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7371727B2 (en) | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7772188B2 (en) * | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| CA2619650A1 (en) | 2005-08-19 | 2007-02-22 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| ES2559319T3 (es) * | 2007-06-04 | 2016-02-11 | Synergy Pharmaceuticals Inc. | Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| SG193801A1 (en) | 2008-08-15 | 2013-10-30 | Ironwood Pharmaceuticals Inc | Linaclotide-containing formulations for oral administration |
| US20120039949A1 (en) | 2008-09-04 | 2012-02-16 | Ironwood Pharmaceuticals, Inc. | Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration |
| GEP20166435B (en) * | 2009-11-09 | 2016-02-25 | Ironwood Pharmaceuticals Inc | Treatments for gastrointestinal disorders |
| US8748575B2 (en) | 2010-06-09 | 2014-06-10 | Combimab, Inc. | Therapeutic peptides |
-
2010
- 2010-11-09 GE GEAP201012738A patent/GEP20166435B/en unknown
- 2010-11-09 BR BR112012011730A patent/BR112012011730A2/pt not_active IP Right Cessation
- 2010-11-09 AR ARP100104153A patent/AR078950A1/es unknown
- 2010-11-09 PH PH1/2012/500916A patent/PH12012500916B1/en unknown
- 2010-11-09 TW TW099138547A patent/TWI482626B/zh not_active IP Right Cessation
- 2010-11-09 MX MX2014016035A patent/MX350046B/es unknown
- 2010-11-09 JP JP2012538087A patent/JP5913115B2/ja not_active Expired - Fee Related
- 2010-11-09 KR KR1020127014811A patent/KR20120115495A/ko not_active Abandoned
- 2010-11-09 EA EA201290322A patent/EA022817B1/ru not_active IP Right Cessation
- 2010-11-09 US US13/508,843 patent/US20140179607A9/en not_active Abandoned
- 2010-11-09 AU AU2010314866A patent/AU2010314866B2/en not_active Ceased
- 2010-11-09 UY UY0001033018A patent/UY33018A/es not_active Application Discontinuation
- 2010-11-09 NZ NZ599751A patent/NZ599751A/en not_active IP Right Cessation
- 2010-11-09 SG SG10201407403UA patent/SG10201407403UA/en unknown
- 2010-11-09 ES ES10782095.3T patent/ES2620153T3/es active Active
- 2010-11-09 US US12/942,887 patent/US8507447B2/en active Active
- 2010-11-09 WO PCT/US2010/056042 patent/WO2011057272A1/en not_active Ceased
- 2010-11-09 UY UY0001033017A patent/UY33017A/es not_active Application Discontinuation
- 2010-11-09 CN CN201080060997.XA patent/CN102812038B/zh not_active Expired - Fee Related
- 2010-11-09 MX MX2012005368A patent/MX2012005368A/es active IP Right Grant
- 2010-11-09 CA CA2779482A patent/CA2779482A1/en not_active Abandoned
- 2010-11-09 UA UAA201206987A patent/UA114274C2/uk unknown
- 2010-11-09 EP EP10782095.3A patent/EP2499154B1/en active Active
-
2012
- 2012-05-03 IL IL219596A patent/IL219596A0/en unknown
- 2012-05-07 CL CL2012001186A patent/CL2012001186A1/es unknown
- 2012-05-07 ZA ZA2012/03342A patent/ZA201203342B/en unknown
- 2012-05-16 CO CO12081055A patent/CO6551683A2/es active IP Right Grant
- 2012-06-06 CR CR20120303A patent/CR20120303A/es unknown
- 2012-06-08 EC ECSP12011962 patent/ECSP12011962A/es unknown
-
2013
- 2013-03-14 US US13/830,656 patent/US8946158B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20120303A (es) | Tratamientos para trastornos gastrointestinales | |
| CR20110580A (es) | Compuestos vinil indazolilo | |
| CR20120202A (es) | Métodos y composiciones para tratar cáncer | |
| CL2017001459A1 (es) | Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología | |
| BR112019012062A2 (pt) | tratamento de uma doença do trato gastrointestinal com um inibidor de jak e dispositivos | |
| CO6791571A2 (es) | Moduladores de la proteína tirosina quinasa 7 (ptk7) para el tratamiento diagnóstico o profilaxis de trastornos neoplásicos | |
| BR112013020500A8 (pt) | anticorpo isolado, recombinante ou purificado | |
| UY34165A (es) | ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?. | |
| MX391175B (es) | Macrociclos peptidomimeticos. | |
| CO6791605A2 (es) | Métodos de tratamiento de trastornos asociados con el fgf21 | |
| MX2011007763A (es) | Metodos y composiciones para tratamiento de cancer de pulmon. | |
| MX2012006549A (es) | Composiciones y metodos que comprenden variantes de proteasa. | |
| CO7071129A2 (es) | Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento | |
| EA201490029A1 (ru) | Соединения, ингибирующие металлоферменты | |
| MX2016001963A (es) | Metodo de seleccion. | |
| ECSP11011541A (es) | Antagonistas de la trayectoria hedgehog de ftalazina disustituida | |
| HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| MX2020004724A (es) | Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. | |
| CO6801724A2 (es) | Composiciones y métodos para el tratamiento de la mielofibrosis | |
| MX345287B (es) | Nuevas composiciones para tratar cmt y trastornos relacionados. | |
| MX2015003909A (es) | Antiandrogenos para el tratamiento del cancer de prostata resistente a la castracion no metastasico. | |
| CR20120035A (es) | Terapia combinatoria de un anticuerpo anti-cd20 afucosilado con fludarabina y/o mitoxantrona | |
| ES2606627T8 (es) | Anticuerpos específicos anti-CD160 para el tratamiento de trastornos oculares basados en la neoangiogénesis | |
| CY1120877T1 (el) | Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης | |
| UY34575A (es) | Composiciones y métodos para el tratamiento de diabetes y/u obesidad |